Two Bespoke CAR-T Regimens Shine for Refractory B-Cell Lymphoma

Two CAR-T treatments — one from Gilead Sciences and another from Bristol Myers Squibb (BMS) — trounced standard-of-care as second-line therapies for patients with relapsed or refractory large B-cell lymphomas in two late-stage studies.
Source: Drug Industry Daily